Efficacy and tolerability of an undenatured type II collagen supplement in modulating knee osteoarthritis symptoms: a multicenter randomized, double-blind, placebo-controlled study

Lugo JP, Saiyed ZM, Lane NE · Nutrition Journal

UC-II reduced total WOMAC significantly more than both placebo and glucosamine+chondroitin at day 180 (WOMAC change about -33% vs -14% placebo), with benefits across pain, stiffness, and function subscales; G+C did not separate from placebo.

Population

Adults with moderate-to-severe knee osteoarthritis, multicenter

Intervention

UC-II 40 mg/day for 180 days

Comparator

Placebo and glucosamine 1500 mg + chondroitin 1200 mg daily

Limitations

Funded by InterHealth (manufacturer) with company authors; the only placebo-controlled OA trial of UC-II of this size — needs independent replication.